Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review). (PubMed, Oncol Lett) - Jul 24, 2026 - "Several inhibitors (e.g., CI-8993 and SNS-101) targeting VISTA have already entered phase I/II clinical trials. Through its dual mechanisms of directly inhibiting T-cell activation and indirectly modulating the TME, VISTA constitutes a key component of tumor immune evasion, offering a vital target for cancer immunotherapy."
IO biomarker • Journal • Review • Oncology
|
|
Ben Yang; Guohui Wang; Kunning Yang; Meihua Qu; Shubo Wang; Ying Chen
|